Please login to the form below

Not currently logged in
Email:
Password:

Bain Capital

This page shows the latest Bain Capital news and features for those working in and with pharma, biotech and healthcare.

Coronavirus disruption scuppers Curium Pharma sale

Coronavirus disruption scuppers Curium Pharma sale

Three potential buyers for Curium – said to include investment groups Nordic Capital, Bain Capital and CVC Capital Partners – are said to have lowered their bids for France-based Curium amid turmoil

Latest news

  • Editas CEO exits the CRISPR firm ahead of first clinical trial Editas CEO exits the CRISPR firm ahead of first clinical trial

    managing director at investment group Bain Capital, and a few months after chief medical officer Gerald Cox also stepped down.

  • Pfizer spins out SpringWorks Therapeutics biotech Pfizer spins out SpringWorks Therapeutics biotech

    funding from the drugmaker plus venture capitalists Bain Capital and Orbimed and medical charity LifeArc. ... Pfizer is contributing both equity capital and royalty- and milestone-bearing licenses to the experimental therapies.

  • No deal for Stada as private equity takeover bid collapses No deal for Stada as private equity takeover bid collapses

    Bain Capital and Cinven's planned buyout of Germany's Stada has failed at the last hurdle, with too few of Stada's shareholders agreeing to the deal by the deadline. ... Stada's board had lent its support to the Bain-Cinven offer over a rival 58 per

  • Private equity firms agree deal to take over Stada Private equity firms agree deal to take over Stada

    Cinven and Bain Capital beat out competition from Advent International. The board of German pharma company Stada has agreed to a takeover deal with two of three interested private equity companies, ... Cinven and Bain Capital made what Stada said was the

  • Stada opens books to let formal bidding commence Stada opens books to let formal bidding commence

    Cinven, Advent International and Bain Capital now have opportunity to revise their bids. ... The three interested parties - confirmed as Cinven, Advent International and Bain Capital - will now all receive the "same level of information" and so have the

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    High-profile disinvestments include those by Pfizer and Eli Lilly. However, Pfizer has since announced that, together with investment firm Bain Capital, it has created a new drug company called Cerevel

  • Deal Watch - May 2017 Deal Watch - May 2017

    Intas (pharma). 106. Bain and others. Investment. Dicerna (biotech). 70. M&A without debt. ... 4, 750 (incl. debt). Stada (DE). Bain Capital and Cinven. Company acquisition.

  • Deal Watch February 2017 Deal Watch February 2017

    A third suitor is believed to be another PE firm, Bain Capital.

  • Deal Watch February 2016 Deal Watch February 2016

    A couple of weeks later Stryker paid $1.28bn (approximately 2.5 x sales) to buy Physio-Control from Bain Capital. ... Founded in the 1950s, Physio-Control is a pioneer of defibrillator/monitor technologies and was owned by Lilly and then Medtronic before

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics